Art. -Nr.: HY-B1228

Ribostamycin sulfate

(Synonyms: Vistamycin sulfate)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant K_D of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.55%
CAS. Nr.: 53797-35-6
Formel: C₁₇H₃₆N₄O₁₄S
Molecular Weight:552.55

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Ribostamycin sulfate Chemical Structure

CAS. Nr.: 53797-35-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[4]

Aminoglycoside

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

In Vitro

Ribostamycin sulfate can bind to purified bovine protein disulfide isomerase (PDI) with a dissociation constant of 319 μM; it can inhibit the chaperone activity of purified bovine PDI, but does not inhibit the autodegradation activity of purified bovine PDI^[1].
Ribostamycin (0.25-64 μg/mL; 14 h) sulfate potently inhibits Haemophilus influenzae ATCC 49247 (MIC = 0.5 μM), Streptococcus pneumoniae ATCC 49619 (MIC = 7.2 μM), and three Escherichia coli strains (ATCC 4157, ATCC 12435, ATCC 10798; MIC range 0.9-7.2 μM), shows moderate activity against two other E. coli strains, and has very weak or no activity against Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis strains in vitro^[2].
Ribostamycin (0.25-64 μg/mL plus 2640 μM EDTA (HY-Y0682); 14 h) sulfate co-treatment with EDTA reduces the MIC of ribostamycin 8-fold against β-lactam-resistant Escherichia coli ATCC 35218, has no effect on its activity against E. coli ATCC 25922 or Pseudomonas aeruginosa ATCC 27853, and reduces its MIC against Staphylococcus aureus ATCC 12600 to <0.1 μM in vitro^[2].
Ribostamycin (68 h) sulfate exhibits no cytotoxicity against HEK293 and MDCKII kidney cells^[2].
Ribostamycin (72 h for MIC, 72 h exposure followed by 3-week subculture for MBC) sulfate shows no significant in vitro inhibitory or borreliacidal activity against 11 Borrelia burgdorferi sensu lato isolates^[3].
Ribostamycin (500 μM-1 mM) sulfate forms linear oligomers that mediate the assembly of citrate-capped AuNPs (40 nm, 60 nm, 80 nm, 100 nm) into visible linear structures, with the most robust assemblies formed with 40 nm and 60 nm AuNPs^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 53797-35-6
Appearance Solid
Molecular Weight 552.55
Formel C₁₇H₃₆N₄O₁₄S
Color White to off-white
SMILES

O=S(O)(O)=O.O[C@@H]([C@H](O)[C@@H](CN)O1)[C@@H](N)[C@@]1([H])O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@]2([H])O[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O
Synonyms

Vistamycin sulfate
Structure Classification
- Antibiotics
- Other Antibiotics
- Antibiotics
- Resistance Selection
Initial Source
- Microorganisms
Streptomyces ribosidicus
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

J Pharm Biomed Anal

Development and validation of a sensitive LC-MS/MS method without derivatization/ion-pairing agents for etimicin quantification in rat plasma, internal ear and kidney. [Abstract]

2017 Nov 30:146:96-102. PMID: 28881316

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 130 mg/mL (235.27 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8098 mL

9.0490 mL

18.0979 mL

5 mM

0.3620 mL

1.8098 mL

3.6196 mL

10 mM

0.1810 mL

0.9049 mL

1.8098 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (90.49 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Horibe T, et al. Ribostamycin Inhibits the Chaperone Activity of Protein Disulfide Isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-972.

[2]. Kong J, et al. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol. 2020;11:1718. Published 2020 Jul 29. [Content Brief]

[3]. Hunfeld KP, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001;17(3):203-208. [Content Brief]

[4]. Zheng T, et al. Linear self-assembly formation between gold nanoparticles and aminoglycoside antibiotics. Colloids Surf B Biointerfaces. 2018;164:185-191. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	1.8098 mL	9.0490 mL	18.0979 mL	45.2448 mL
	5 mM	0.3620 mL	1.8098 mL	3.6196 mL	9.0490 mL
	10 mM	0.1810 mL	0.9049 mL	1.8098 mL	4.5245 mL
	15 mM	0.1207 mL	0.6033 mL	1.2065 mL	3.0163 mL
	20 mM	0.0905 mL	0.4524 mL	0.9049 mL	2.2622 mL
	25 mM	0.0724 mL	0.3620 mL	0.7239 mL	1.8098 mL
	30 mM	0.0603 mL	0.3016 mL	0.6033 mL	1.5082 mL
	40 mM	0.0452 mL	0.2262 mL	0.4524 mL	1.1311 mL
	50 mM	0.0362 mL	0.1810 mL	0.3620 mL	0.9049 mL
	60 mM	0.0302 mL	0.1508 mL	0.3016 mL	0.7541 mL
	80 mM	0.0226 mL	0.1131 mL	0.2262 mL	0.5656 mL
	100 mM	0.0181 mL	0.0905 mL	0.1810 mL	0.4524 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Ribostamycin sulfate

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ribostamycin sulfate

Glycoside Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Microbial Metabolite Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Ribostamycin sulfate

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ribostamycin sulfate

Glycoside Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Microbial Metabolite Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Ribostamycin sulfate

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ribostamycin sulfate Related Classifications

HY-B1228 Related Classifications